These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 564247)

  • 21. Comparative effects of alfacalcidol and parathyroidectomy with vitamin D in hyperparathyroid renal bone disease.
    Cundy T; Kanis JA; Earnshaw M; Woods CG
    Q J Med; 1986 Jul; 60(231):659-70. PubMed ID: 3763817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium metabolism in renal failure.
    David DS
    Am J Med; 1975 Jan; 58(1):48-56. PubMed ID: 1090150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of whole body and regional assessments of calcium balance in renal osteodystrophy in the response to 1 alpha-hydroxy vitamin D3.
    Naik RB; Robertson PW; Robinson BH; Dabek JT; James HM; Kanis JA
    Proc Eur Dial Transplant Assoc; 1977; 14():425-32. PubMed ID: 600960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
    [No Abstract]   [Full Text] [Related]  

  • 25. Calcifediol in chronic renal insufficiency. Skeletal response.
    Teitelbaum SL; Bone JM; Stein PM; Gilden JJ; Bates M; Boisseau VC; Avioli LV
    JAMA; 1976 Jan; 235(2):164-7. PubMed ID: 946022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
    Weber K; Goldberg M; Stangassinger M; Erben RG
    J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of 1alpha-hydroxyvitamin D3 in the management of patients undergoing parathyroidectomy.
    Parsons V; Jones R; Weston M; Lucas P; Snowden S; Keenan J; Packham D
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():223s-224s. PubMed ID: 606420
    [No Abstract]   [Full Text] [Related]  

  • 28. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.
    Tougaard L; Sorensen E; Brochner-Mortensen J; Christensen MS; Rodbro P; Sorensen AW
    Lancet; 1976 May; 1(7968):1044-7. PubMed ID: 57451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.
    Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S
    Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of 1alpha-hydroxyvitamin D3 in patients with chronic renal failure, with particular emphasis on the renal handling of phosphate.
    Madsen S; Olgaard K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():85s-89s. PubMed ID: 606430
    [No Abstract]   [Full Text] [Related]  

  • 33. Cessation of bone loss in chronic renal failure by 1-alpha-hydroxyvitamin D3: a controlled trial.
    Madsen S; Olgaard K; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1978; 15():517-23. PubMed ID: 311003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3.
    Postlethwaite RJ; Houston IB
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
    Pierides AM; Ellis HA; Simpson W; Dewar JH; Ward MK; Kerr DN
    Lancet; 1976 May; 1(7969):1092-5. PubMed ID: 57505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in bone histomorphometry and bone mineral during treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
    Lindholm TS; Nilsson OS; Elmstedt E; Eriksson SA; Lindholm TC; Kyhle BR
    Acta Vitaminol Enzymol; 1981; 3(3):170-6. PubMed ID: 7347489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 38. 1alpha-hydroxyvitamin D3 in primary hyperparathyroidism.
    Boyle IT; Fogelman I; Boyce B; Thomson JE; Beastall GH; McIntosh WB; McLennan I
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():215s-222s. PubMed ID: 606419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of senile osteoporosis with 1alpha-hydroxyvitamin D3.
    Sørensen OH; Andersen RB; Christensen MS; Friis T; Hjorth L; Jørgensen FS; Lund B; Melsen F; Mosekilde L
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():169s-175s. PubMed ID: 342143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curative effects of 1alpha-hydroxycholecalciferol on calcium metabolism and bone disease in patients with chronic renal failure.
    Hirooka M; Wako H; Kaneko C; Ishikawa M; Sasaki S
    J Nutr Sci Vitaminol (Tokyo); 1975; 21(4):277-85. PubMed ID: 1214180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.